Please ensure Javascript is enabled for purposes of website accessibility

Why Sagent Pharmaceuticals Inc. Jumped Today

By Brian Orelli, PhD - Jan 13, 2016 at 3:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Confirmed buyout rumors give investors confidence in an exit.

What: Sagent Pharmaceuticals (NASDAQ: SGNT) surged this morning and was up as much as 19% today after Reuters reported that the company has hired an investment bank to solicit bids to buy the generic-drug maker.

So what: Reuters appears to have multiple sources that confirmed the rumor -- and even named the investment bank, Perella Weinberg Partners -- so it seems likely that Sagent Pharmaceuticals really is looking for a buyer. The JP Morgan Healthcare Conference is going on right now, so it's certainly a good time to shop a company around since all the potential buyers are hanging out in San Francisco this week.

Sagent Pharmaceuticals had a rough 2015, falling 38% because it failed to meet its own expectations. The company started the year with 2015 guidance of net revenue in the range of $325 million to $375 million. In March, founder and CEO Jeffrey Yordon retired and the company's president, James Hussey, left the company. By the third-quarter conference call in November, the revenue guidance was down to a range of $305 million to $330 million.

Now what: Buying a company solely because you hope it'll get sold is akin to gambling since it's hard to know whether other companies might be interested in buying at the current price.

That being said, there's a lot of consolidation in the generic-drug business where small margins make it advantageous to be larger. Because the acquirer can reduce redundancy, it's possible that Sagent Pharmaceuticals could be taken out at a higher price than investors are willing to pay for the stand-alone company.

Adding Sagent Pharmaceuticals' $300 million in revenue isn't going to amount to much for one of the large players like Teva Pharmaceutical or Pfizer (PFE -1.18%). I doubt Pfizer would even consider buying Sagent; the $17 billion purchase of Hospira is more Pfizer's size. But it's certainly possible for a smaller company to buy Sagent Pharmaceuticals to try to make itself an acquisition target for Pfizer or some other larger pharmaceutical.

It seems more likely than not that a deal gets done, but without knowing what other companies might be willing to offer, it's risky buying Sagent Pharmaceuticals right now. If a deal doesn't get done, it's not hard to see the price falling below where it was before the Reuters report.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.27 (-1.18%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.